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Abstract
Background:  All the peroxisome proliferator activated receptors (PPARs) are found to be
expressed in bone cells. The PPARγ agonist rosiglitazone has been shown to decrease bone mass
in mice and thiazolidinediones (TZDs) have recently been found to increase bone loss and fracture
risk in humans treated for type 2 diabetes mellitus. The aim of the study was to examine the effect
of the PPARα agonist fenofibrate (FENO) and the PPARγ agonist pioglitazone (PIO) on bone in
intact female rats.
Methods: Rats were given methylcellulose (vehicle), fenofibrate or pioglitazone (35 mg/kg body
weight/day) by gavage for 4 months. BMC, BMD, and body composition were measured by DXA.
Histomorphometry and biomechanical testing of excised femurs were performed. Effects of the
compounds on bone cells were studied.
Results: The FENO group had higher femoral BMD and smaller medullary area at the distal femur;
while trabecular bone volume was similar to controls. Whole body BMD, BMC, and trabecular
bone volume were lower, while medullary area was increased in PIO rats compared to controls.
Ultimate bending moment and energy absorption of the femoral shafts were reduced in the PIO
group, while similar to controls in the FENO group. Plasma osteocalcin was higher in the FENO
group than in the other groups. FENO stimulated proliferation and differentiation of, and OPG
release from, the preosteoblast cell line MC3T3-E1.
Conclusion: We show opposite skeletal effects of PPARα and γ agonists in intact female rats.
FENO resulted in significantly higher femoral BMD and lower medullary area, while PIO induced
bone loss and impairment of the mechanical strength. This represents a novel effect of PPARα
activation.
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Background
Peroxisome proliferator activated receptors (PPARs) are
nuclear transcription factors that modulate the expression
of a variety of genes involved in lipid metabolism and fat
storage [1-3]. The PPAR family consists of three subtypes,
PPARα, β/δ and γ (with splice variants γ 1, 2 and 3) ubiq-
uitously expressed, but with a tissue specific distribution
[1,2]. All PPAR subtypes have been identified in osteob-
lasts [4] and osteoclasts [5-7]. PPAR ligands include fatty
acids, eicosanoids, nonsteroidal inflammatory agents and
a heterogeneous class of chemicals [1-3,8]. Thiazolidine-
diones (TZDs) are PPARγ agonists, currently used for the
treatment of insulin resistance and type 2 diabetes melli-
tus [8], while fibrates are mainly PPARα agonists that are
efficient in lowering elevated triglyceride concentrations
[9]. TZDs have been shown to inhibit osteoclast differen-
tiation and bone resorption [7,10,11], while others report
a stimulatory effect on osteoclastogenesis and bone
resorption [12]. The fibrates fenofibrate and bezafibrate
have been found to inhibit osteoclastogenesis [11,13].
Previous studies have shown that the PPARγ agonist ros-
iglitazone decreases bone mass in mice [14,15], and
enhances bone loss induced by estrogen deprivation in
rats [16]. Moreover, TZDs have been associated with bone
loss at the whole body, lumbar spine and trochanter in
elderly women, but not men, with type 2 diabetes [17].
Recent studies have revealed that rosiglitazone treatment
causes elevated fracture rates in women with type 2 diabe-
tes [18], and also decreases bone formation and bone
mineral density (BMD) in healthy postmenopausal
women [19].
We have previously demonstrated the presence of leptin
and its receptors in human osteoblasts and shown that
leptin stimulates osteoblast proliferation, differentiation
and mineralization [20,21]. TZD administration to rats
has shown to reduce the plasma levels of leptin in spite of
increase in fat mass [22,23], which may imply that leptin
is involved in the skeletal effects observed after treatment
with rosiglitazone [14-16]. In contrast, the plasma levels
of the adipokine adiponectin are elevated in rats [24,25],
as well as humans receiving TZDs [26]. Adiponectin con-
centrations have also been reported to be elevated after
fenofibrate therapy in patients with hypertriglyceridemia
[27].
In the present study we examined the long-term effects of
the PPARα agonist fenofibrate and the PPARγ agonist
pioglitazone on the rat skeleton in vivo, using bone mass
measurements, histomorphometry and biomechanical
testing. The levels of osteocalcin and fragments of colla-
gen type I in plasma, and leptin and adiponectin levels in
plasma and femurs were analyzed. Moreover, the in vitro
effects of fenofibrate and pioglitazone on cytokine release,
proliferation and differentiation of a preosteoblast cell
line, and differentiation and activity of human osteoclasts
were assessed.
Methods
Fenofibrate was provided by one of the co-authors, and
pioglitazone was kindly provided by Eli Lilly, Norway.
Methylcellulose (M7140, Sigma-Aldrich, St.Louis, MO)
was used as vehicle for both drugs. Female Fischer-344
rats were purchased from Møllegaard's Breeding Center
(Skensved, Denmark).
Study design
The Animal Welfare Committee at Trondheim University
Hospital approved this study. Thirty-five two-month-old
female Fischer rats (203 ± 11.5 g) were housed solely in
wire-top cages with aspen woodchip bedding from B&K
Universal Ltd. Room temperature was 24 ± 1.0°C with a
relative humidity of 40%–50% and a 12-h light/dark
cycle. The Rat and Mouse Diet of B&K, and tap water were
provided ad libitum. One group received methylcellulose
(control, n = 12), and the other two groups methylcellu-
lose with either fenofibrate (n = 11) or pioglitazone (n =
12), 35 mg/kg body weight daily given for 4 months by
gavage. The dose of pioglitazone was chosen on the back-
ground of previous studies on the long-term skeletal
effects of TZDs in rodents [14,16,28]. The dose of fenofi-
brate was chosen according to other studies with long-
term fenofibrate treatment in rats [29,30].
The rats were weighed at the start and weekly throughout
the study. Before all procedures and sacrifice, the animals
were anesthetized with 2.0 ml/kg body weight of a combi-
nation of fluanison (2.5 mg/ml), fentanyl (0.05 mg/ml),
and midazolam (1.25 mg/ml). Blood was collected by
heart puncture during the finale anesthezia, and stored at
-80°C until assaying. The liver weights were also regis-
tered. Both femurs were collected and stored at -80°C for
further analyses.
Dual X-ray absorptiometry (DXA) measurements
Bone mineral density (BMD) and bone mineral content
(BMC) in femur and whole body, fat mass and lean mass
were measured by DXA in intact animals, using a Hologic
QDR 4500A, and small animal software. Measurements
were performed in duplicate at the start and the end of the
study in intact animals. Coefficients of variation were
0.6% for whole body BMD, 0.7% for femur BMD, 0.5%
for whole body BMC, 3.0% for femur BMC, 2.2% for total
fat content, and 0.3% for lean body mass.
Histomorphometry
Histomorphometry of the left femur was performed as
described previously and was evaluated by two persons
(27). Transverse sections were cut close to the patellar
ridge and also 5.0 mm proximal from it. They wereBMC Endocrine Disorders 2009, 9:10 http://www.biomedcentral.com/1472-6823/9/10
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grounded to a thickness of 50 um. The sections close to
the patellar ridge were used for calculation of trabecular
bone volume (TBV%), and proximal sections were used
for calculation of cortical thickness. The sections for calcu-
lation of TBV% were stained with Goldener. For calcula-
tion of TBV% a Merz grid at a magnification of 10 × 10
was used. As many squares as possible, usually about 9–
11, were calculated. For calculation of cortical thickness
the central point of the medullary canal was identified. By
means of an eyepiece the diameters were calculated in
four directions with a 45 degrees angle between each.
Medullary, cortical and total cross-sectional areas were
calculated from the mean values. All histomorphometric
measurements were performed blindly.
Biomechanical testing
The right femurs were thawed in Ringers® solution before
mechanical testing of the femoral shaft and the femoral
neck was performed. The diaphyses were fractured 18.7
mm from the femoral condyles in three point cantilever
bending as previously described [31]. The proximal femur
was fixed in a clamp, the cam of the rotating wheel
engaged the femoral condyles and a fulcrum positioned
anteriorly 18.7 mm from the condyles was the third point
of force application. All tests were done at a loading rate
of 0.095 radians/second (5.43°/second). The load in the
test apparatus, an MTS 858 Mini Bionix® Axial/Torsional
Test System (MTS Systems Corporation, Minnesota, USA),
was measured with a MTS Test Star TM Sensor Cartridge
Force 250 N load cell and registered in MTS Test Star II
software. Ultimate moment, ultimate energy absorption,
stiffness and deflection were read directly or calculated
from the computer recordings [32].
Assessment of protein in femur
After biomechanical analyses, the right femurs were
homogenized by crushing in liquid nitrogen, and 200 mg
tissue of each sample was lysed in Trizol (Invitrogen, CA,
USA) followed by protein isolation according to the man-
ufacturer's instructions.
Leptin, adiponectin, insulin, osteocalcin, osteoprotegerin 
(OPG) and bone resorption marker analyses in rat plasma 
and protein fraction of rat femur and OPG, RANKL and 
total protein analyses in medium from MC3T3-L1 cells
Using radioimmunoassay (RIA) (Linco Research, St.
Charles, Missouri 63304, USA), leptin and adiponectin
levels were quantified in plasma and in the isolated fem-
oral protein fraction, and insulin and OPG levels were
measured in plasma. Detection limits were 3.0 pg/ml for
leptin, 0.78 ng/ml for adiponectin, 18.6 pg/ml for insulin,
and 2.3 pg/ml for OPG. Intra- and interassay variations
for all RIAs were < 4.5% and < 9.0%, respectively.
Osteocalcin in plasma was determined by a Rat-MID
Osteocalcin enzyme-linked immunosorbent assay kit
(Nordic Bioscience Diagnostics A/S, Denmark), according
to the manufacturer's protocol. The detection limit was 50
ng/ml, and intra- and interassay variations were 5.0% and
5.5%, respectively. Bone resorption markers in plasma
(fragments of type 1 collagen) were analyzed by a RatLaps
ELISA kit (Nordic Bioscience Diagnostics A/S) according
to the instructions from the manufacturer. The detection
limit was 3.0 ng/ml, and intra- and interassay variations
were 5.6% and 10.5%, respectively.
The concentration of OPG in the mouse cell line MC3T3-
E1 culture media was determined by ELISA as described
by the manufacturer (RnD Systems, USA) using anti-
mouse OPG-antibody and biotinylated anti-mouse OPG.
Detection was performed by labeling with streptavidin-
horseradish peroxidase (R&D Systems) and adding 1, 2
phenylenediamine dihydrochloride (OPD) (Dako, Glos-
trup, Denmark) as substrate. The enzymatic reaction was
stopped after 20 min by adding 100 μl of 0.5 M H2SO4 to
each well. The optical density (OD) was measured as
absorbance at 490 nm. Recombinant murine OPG was
used as standard. The detection limit was 10 pg/ml, and
intra-assay and inter-assay variabilities were less than 15%
and 9.0%, respectively. The amount of OPG was related to
the amount of total protein in each sample. RANKL con-
centration in culture media was determined by an immu-
noassay kit for quantitative determination of free sRANKL
from mouse and rat (Biomedica, Vienna, Austria) accord-
ing to the manufacturer's protocol. The amount of RANKL
was related to the amount of total protein in each sample.
The amount of total protein in media was determined
using Sigma Microprotein PR assay kit with Protein Stand-
ard Solution Calibrator (Sigma Diagnostics, Dorset, UK)
according to the manufacturer's protocol. Analyses were
performed using the Cobas Mira chemistry analyzer
(Roche Diagnostics, Germany). Intra-assay and inter-
assay variabilities were less than 2.4% and 3.2% respec-
tively. Detection range for the assay was 10-2.0 × 103 mg/l.
Cells and reagents
MC3T3-E1 (mouse preosteoblasts, ATCC) cells were
maintained in α-MEM (Invitrogen) supplemented with
10% fetal calf serum (FCS) (EuroClone, Great Britain), 1
mM Na- pyruvate (Gibco BRL, Life Technologies Ltd, Scot-
land), 0.1 mg/ml L-glutamine (Gibco) and 10 U/ml pen-
icillin/streptomycin (Gibco).
Commercially available human primary precursor osteo-
clasts, differentiation medium and an Osteolysis Assay kit
(Lonza Walkersville, Inc., MD, USA) were used for in vitro
assays of human osteoclast differentiation and activity
according to the manufacturer's protocol.
Osteoblast differentiation
To study whether fenofibrate and pioglitazone affected
osteoblast differentiation, MC3T3-E1 cells were seeded inBMC Endocrine Disorders 2009, 9:10 http://www.biomedcentral.com/1472-6823/9/10
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6-wells plates (3.0 × 105 cells/well) and cultured until con-
fluence (3 days). The cells were then cultured for up to 12
days in α-MEM/10% FCS, with or without fenofibrate or
pioglitazone. Medium was changed every second day. The
relative mRNA expression of the osteoblast differentiation
markers including alkaline phosphatase (ALP), bone sia-
loprotein (BSP), CD44, collagen 1, osteocalcin and oste-
opontin was studied. The relative mRNA expression of
PPARα, PPARγ and of the adipocyte differentiation gene
lipoprotein lipase (LPL) was also determined.
Proliferation assay
Proliferation was studied using a kit from Roche Molecu-
lar Biochemicals, Mannheim, Germany. Briefly, MC3T3-
E1 cells (4 × 103 cells/well) were seeded in 96 well plates,
and cultured for 24 h. Cells were washed once with 180 μl
serum-free medium, before addition of new medium with
or without test substances. After 4 h, 5-bromo-2'-deoxyu-
ridine (BrdU)-labeling solution was added, and the cells
were cultured for additional 18 h before incorporation of
BrdU was measured as described by the manufacturer.
After removing the labeling medium, cells were fixed and
genomic DNA denaturized by adding 150 μl FixDenat per
well for 30 min at room temperature. FixDenat-solution
was removed and 100 μl of peroxidase-conjugated anti-
BrdU antibody solution was added per well, followed by
incubation at room temperature for 90 min. The cells
were washed three times with 200 μl washing solution
before 100 μl of substrate Luminol/4-idophenol was
added. After 3 min, chemiluminescence was measured
(RLU = relative luminescence units) in a micro plate lumi-
nometer (Fluoroscan Ascent FL, Labsystems).
mRNA isolation and cDNA synthesis
Cells were homogenized and lysed in lysis/binding buffer
and mRNA was isolated using magnetic beads (oligo
(dT)25) as described by the manufacturer (Dynal AS, Oslo,
Norway). Beads containing mRNA were resuspended in
10 mM Tris-HCl, pH 8.0, and stored at -80°C until use.
mRNA-containing solution was applied directly to obtain
a first-strand complementary DNA (cDNA) using the
iScript cDNA Synthesis Kit with oligo(dT) (Bio-Rad, CA,
USA). cDNA samples were diluted 1:2 with nuclease free
water.
Real time PCR quantification
Reactions were performed and monitored using Strata-
gene's Mx3000P Real-time PCR system. The 2× iQ SYBR
Green Supermix was based on iTaq DNA polymerase
(Bio-Rad, Oslo, Norway). cDNA samples were analyzed
both for the genes of interest and reference genes (β-actin)
The amplification program consisted of a preincubation
step for denaturation of the template cDNA (5 min,
95°C), followed by 40 cycles consisting of a denaturation
step (30 s, 95°C), an annealing step (30 s, 60°C) and an
extension step (30 s, 72°C). The Ct value, defined as the
number of cycles required to produce a detectable product
above background fluorescence, was measured for each
sample, and arbitrary units were calculated using standard
curves that consisted of serial dilutions of cDNA from a
pool of samples or controls containing the highest
amounts of the specific gene analyzed. Contamination by
genomic DNA was ruled out by performing PCR analysis
where RT-enzyme had been omitted in the RT reactions.
β-actin RT-PCR was run in duplicates or triplets as control
to monitor RNA integrity and to be used for normaliza-
tion. Specificity of each primer pair was confirmed by
melting curve analysis and agarose gel electrophoresis,
and PCR products were sequenced for product confirma-
tion. Table 1 show the primer sequences, the expected
sizes of the PCR products and gene bank accession num-
bers used for design of the primer pairs. Intron-spanning
primers were designed using the computer software
Clone. Data is calculated from standard curves, related to
housekeeping gene and presented normalized to
untreated controls at each individual time point.
Osteoclast differentiation and activity
Primary human osteoclast precursor cells and differentia-
tion media containing macrophage colony stimulating
factor (M-CSF) and soluble RANKL were obtained from
Lonza, and cultured according to the provided protocol.
Ten thousand cells per well were seeded in a 96-well plate
in differentiation medium. Fenofibrate or pioglitazone
(10 nM, 0.1, 1.0 and 10 μM) were added in six parallel
wells, and cultured for 12 days before cultures were
stained for tartrate-resistant acid phosphatase (TRAP),
activity using Naphtol AS-BI phosphate and Fast Garnet in
the presence of sodium tartrate, as described by the man-
ufacturer (Sigma-Aldrich, Norway). The number of TRAP
positive, multinuclear (3 or more nuclei) cells was
counted.
Human osteoclast activity was examined using the Oste-
olyse Assay kit (Lonza,). An osteolyse plate was seeded
with 1.0 × 104 human osteoclast precursor cells (Lonza)
per well in medium containing M-CSF and soluble
RANKL and cultured at 37°C for 7 days. Control cells were
seeded with or without RANKL and M-CSF. Culture media
were changed on day 7, and then cultured for another 1 to
3 days with or without fenofibrate (0.1, 1.0 and 10 μM) or
pioglitazone (0.1, 1.0 and 10 μM), with six parallels for
each condition. Cell medium supernatants were collected
on day 8, 9 and 10, and the release of collagen type I was
measured by EIA according to the manufacturer's proto-
col, with the exception that fluorescence was measured by
excitation at 355 nm and emission of 650 nm, instead of
340/615 nm as recommended.
Statistical analyses
Measurements were performed in duplicates or triplets.
Data is expressed as means ± SD. All data were tested forBMC Endocrine Disorders 2009, 9:10 http://www.biomedcentral.com/1472-6823/9/10
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normality with Shapiro-Wilk and D'Agostino & Pearson
omnibus normality tests. Normally distributed parame-
ters were tested with two-tailed unpaired Student t-test, or
one-way ANOVA with Bonferroni's post test, while
parameters that were not normally distributed were tested
with Mann-Whitney's two tailed test, or Kruskal Wallis
test with Dunn's post test. Significance was assumed at P-
values lower than 0.05. Correlations between normally
distributed data sets were analyzed by Pearson's product-
moment correlation coefficient test.
Results
Anthropometric data, body composition and liver weights
There were no differences in body weight, fat mass or lean
mass at the beginning of the study (data not shown). After
4 months of drug administration, the body weight did not
differ between the groups, and no difference in femoral
length was observed, indicating absence of effects on lon-
gitudinal growth (Table 2). The rats given pioglitazone
had significantly higher fat mass (P = 0.01 vs. controls,
and P = 0.0001 vs. the group given fenofibrate). Lean mass
Table 1: Primers used in real-time PCR quantification
Gene Primer Sequence Specie Size (bp) Gene Bank Accession Number
Alcalic phosphatase (ALP) S 5'-AACCCAGACACAAGCATTCC-3' Mouse 151 NM_007431.1
AS 5'-GAGAGCGAAGGGTCAGTCAG-3'
β-actin S 5'-CTGGCTCCTAGCACCATGA-3' Mouse 73 NM_031144.2
AS 5'-AGGCACCAATCCACACAGA-3'
Bone Sialoprotein S 5'-GAAAATGGAGACGGCGATAG-3' Mouse 141 NM_008318.1
AS 5'-ACCCGAGAGTGTGGAAAGTG-3'
CD44 S 5'-CTTCCATCTTGACCCGTTGT-3' Mouse 175 NM_009851.2
AS 5'-ACAGTGCTCCTGTCCCTGAT-3'
Collagen 1 S 5'-AGAGCATGACCGATGGATTC-3' Mouse 177 NM_007742.3
AS 5'-CCTTCTTGAGGTTGCCAGTC-3'
Lipoprotein lipase (LPL) S 5'-GGATAAGCGACTCCTACTTC-3' Mouse 198 NM_008509.1
AS 5'-AGCCAGACTTCTTCAGAGAC-3'
Osteocalcin S 5'-CCGGGAGCAGTGTGAGCTTA-3' Mouse 81 L24431.1
AS 5'-TAGATGCGTTTGTAGGCGGTC-3'
Osteopontin S 5'-GACCACATGGACGACGATG-3' Mouse 498 BC002113.1
AS 5'-TGGAACTTGCTTGACTATCGA-3'
PPARα S 5'-TGAACAAAGACGGGATG-3' Mouse 106 NM_011144.2
AS 5'-TCAAACTTGGGTTCCATGAT-3'
PPARγ S 5'-CAGGCTTCCACTATGGAGTT-3' Mouse 105 NM_011146.1
AS 5'-TCCGGCAGTTAAGATCACAC-3'
PPAR = peroxisome proliferator activated receptor
Table 2: Body composition, femur length, femur and whole body BMC and BMD
Group Control (n = 12) Fenofibrate (n = 11) Pioglitazone (n = 8)
Body weight
(g)
237 ± 14.9 243 ± 9.60 240 ± 8.70
Fat mass
(g)
46.8 ± 13.7 41.2 ± 6.94 62.5 ± 8.42**/###
Lean mass
(g)
184 ± 7.73 195 ± 8.98** 171 ± 8.87**/###
Femur length
(cm)
33.9 ± 0.44 34.1 ± 0.53 33.5 ± 0.57
Femoral BMC
(g)
3.56 ± 0.30 3.78 ± 0.28 3.39 ± 0.26##
Femoral BMD
(g/cm2)
0.245 ± 0.009 0.259 ± 0.001** 0.235 ± 0.001###
Whole body BMC
(g)
7.23 ± 0.36 7.36 ± 0.26 6.87 ± 0.40*/##
Whole body BMD
(g/cm2)
0.159 ± 0.008 0.157 ± 0.005 0.143 ± 0.002***/###
BMC = bone mineral content, BMD = bone mineral density. Data is presented as mean ± SD, *P < 0.05, **P < 0.01, ***P < 0.001 significantly 
different compared to control, ##P < 0.01, ###P < 0.001 significantly different compared to fenofibrate-treated group.BMC Endocrine Disorders 2009, 9:10 http://www.biomedcentral.com/1472-6823/9/10
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was significantly lower in the pioglitazone group com-
pared to controls (P = 0.005) and the fenofibrate group (P
= 0.0001) (Table 2). In the fenofibrate group, fat mass did
not differ from controls, while lean mass was significantly
higher than in control rats (P = 0.006) (Table 2). The
mean liver weight was significantly higher in the fenofi-
brate group compared to controls (9.64 ± 0.85 g and 6.98
± 0.47 g, respectively, P = 0.0001). In the pioglitazone
group, the liver weight was significantly lower (5.79 ±
0.39 g), both compared to controls (P = 0.0168) and to
rats receiving fenofibrate (P = 0.0001). Since lean mass
also include liver weight, the liver weight was subtracted
to correct for this. After this correction, lean mass was still
significantly higher in the fenofibrate group (185.3 ± 8.5
g), both compared to the control (176.4 ± 7.6 g, P  =
0.016) and pioglitazone group (165.6 ± 8.6 g, P  =
0.0001). Corrected lean mass was significantly lower in
the pioglitazone group than in the controls (P = 0.008).
Four animals died in the pioglitazone group, while none
died in the other groups. The cause of death in the piogli-
tazone group was aspiration in connection with gastric
gavage in 3 of the rats, in one of the rats no reason could
be found. No differences in the well-being of the animals
were, however, observed during the study.
Bone mineral content (BMC) and bone mineral density 
(BMD)
There were no differences in femoral and whole body
BMC or BMD at the beginning of the study (data not
shown). After four months of treatment, femur BMC
tended to be higher, albeit not significantly, in the fenofi-
brate group compared to controls, (+ 6.2%, P = 0.08),
while the pioglitazone group had significantly lower
femur BMC compared to the fenofibrate group (-10%, P =
0.0067), but not compared to controls (Table 2). Femoral
BMD was significantly higher in fenofibrate rats (+ 5.8%,
P = 0.004), while femoral BMD was similar in controls
and pioglitazone treated rats (Table 2). The pioglitazone
group had significantly lower femoral BMD than the
fenofibrate group (-10%, P = 0.0003). Whole body BMC
was significantly lower in the pioglitazone group after
four months of treatment, relative to controls (-5.2%, P =
0.047), and relative to the fenofibrate group (-6.6%, P =
0.004). Whole body BMD was significantly lower in the
pioglitazone group compared to controls (-9.8%, P  =
0.0001), and also compared to the fenofibrate group (-
8.4%, P = 0.0001), while there was no difference between
the control group and the fenofibrate group (Table 2).
Histomorphometry and correlation analyses
Trabecular bone volume in the distal femur was lower in
the pioglitazone rats compared to control rats and fenofi-
brate rats (-27%, P = 0.006 and – 25%, P = 0.019, respec-
tively), while no difference was found between the
fenofibrate and the control group (Table 3). The medul-
lary area in distal femur was significantly higher in the
pioglitazone rats compared to the fenofibrate group, (+
14.8%, P = 0.0001), and also significantly higher com-
pared to controls (+ 8.0%, P = 0.05), (Table 3). In contrast
medullary area was lower, in the fenofibrate group com-
pared to controls (-7.2%, P = 0.05). There were no differ-
ences in cortical and total areas between the groups (Table
3). For the total material, there was a significant positive
correlation between lean mass (corrected for liver weight),
femoral BMD (Pearsons r = 0.513, P = 0.0001) and corti-
cal area (Pearsons r = 0.673, P = 0.008).
Biomechanical testing
The ultimate bending moment, deflection and energy
absorption of femoral shafts were significantly lower in
the pioglitazone rats compared to controls (P = 0.007, P =
0.039 and P = 0.014), and compared to the fenofibrate
group (P = 0.019, P = 0.0025 and P = 0.014), while no dif-
ference was found between the fenofibrate group and the
controls (Table 4). Biomechanical parameters in the fem-
oral neck did not differ significantly between the groups
(Table 4).
Leptin and adiponectin measurements
Plasma levels of leptin were significantly lower in both
fenofibrate (P = 0.02) and pioglitazone groups (P = 0.03)
compared to controls (Figure 1A). In femoral bone, the
leptin concentration was lower in pioglitazone rats (P =
0.003 vs. control and P  = 0.03 vs. fenofibrate group),
Table 3: Histomorphometric data for femur
Group Control (n = 12) Fenofibrate (n = 11) Pioglitazone (n = 8)
Trabecular bone
Volume (%)
22.2 ± 5.95 21.70 ± 5.72 16.3 ± 1.38**/#
Total area
(mm2)
6.34 ± 0.40 6.35 ± 0.23 6.61 ± 0.30
Cortical area
(mm2)
3.99 ± 0.29 4.18 ± 0.16 4.05 ± 0.21
Medullary area
(mm2)
2.35 ± 0.25 2.18 ± 0.11* 2.56 ± 0.16###
Data is presented as mean ± SD. *P<0.05, **P < 0.01 significantly different compared to control. #P < 0.05, ###P < 0.001 significantly different 
compared to fenofibrate-treated group.BMC Endocrine Disorders 2009, 9:10 http://www.biomedcentral.com/1472-6823/9/10
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while the fenofibrate group did not differ from controls
(Figure 1B). Plasma levels of adiponectin were signifi-
cantly lower in the fenofibrate group compared to con-
trols (P  < 0.0001) (Figure 1C), while the adiponectin
levels were significantly higher in the pioglitazone group
both compared to controls (P < 0.0001), and to the fenof-
ibrate group (P < 0.0001) (Figure 1C). There were no dif-
ferences in the adiponectin levels in femoral bone
between the groups (Figure 1D).
Insulin, osteocalcin, OPG and bone resorption marker 
measurements
There were no differences in plasma levels of insulin
between the groups (controls: 1.42 ± 0.66 ng/ml, fenofi-
brate group: 1.35 ± 0.69 ng/ml and pioglitazone group:
1.32 ± 0.52 ng/ml). Plasma levels of osteocalcin were sig-
nificantly higher in the fenofibrate group compared to
controls (P = 0.012), while the pioglitazone group did not
differ from controls (Figure 1E). Plasma OPG levels were
significantly lower in the pioglitazone group compared to
controls (P = 0.009), while the fenofibrate group did not
differ from controls (Figure 1F). There were no differences
in plasma levels of bone resorption marker (fragments of
collagen type I) between the groups (data not shown).
Fenofibrate stimulates mRNA expression of osteoblast 
differentiation markers
After 12 days of stimulation, fenofibrate (0.1 μM) signifi-
cantly increased the mRNA expression of ALP, BSP, CD44,
collagen 1, and osteocalcin in MC3T3-E1 cells (Table 5).
Pioglitazone (0.1 μM) increased the relative CD44 mRNA
expression after 12 days of stimulation, but none of the
other osteoblast differentiation genes examined (Table 5).
Other concentrations of both fenofibrate and pioglita-
zone (1.0 μM and 10 μM) were examined, with similar
patterns. The early adipocyte differentiation marker lipo-
protein lipase (LPL) mRNA was not expressed at day 0,
but was low and equally expressed in all cells at day 4, 8
and 12 of stimulation (Table 5). PPARα mRNA expression
was significantly enhanced compared to control by both
fenofibrate and pioglitazone after 4 days, and also after 8
and 12 days by fenofibrate. There was, however, no detect-
able expression of PPARα mRNA in pioglitazone stimu-
lated cells after 12 days. PPARγ expression was equally
expressed in all cells throughout the stimulation period
(Table 5).
Fenofibrate stimulates proliferation of and OPG release 
from preosteoblasts
Fenofibrate (1.0 nM – 1.0 μM) increased proliferation of
MC3T3-E1 preosteoblasts, whereas pioglitazone had no
effect (Figure 2).
MC3T3-E1 cells were treated with fenofibrate and piogli-
tazone (1.0 nM to 10 uM) for 12, 24, 48 and 72 h to study
the effect on release of OPG and RANKL. Fenofibrate
increased OPG release in a dose-dependent manner after
12–48 h stimulation (P < 0.05) (Figure 3A). In contrast,
pioglitazone had no effect on OPG release from MC3T3-
E1 cells (Figure 3B). Neither fenofibrate nor pioglitazone
Table 4: Mechanical properties of femoral neck and shaft
Group Control (n = 12) Fenofibrate (n = 11) Pioglitazone (n = 8)
Moment
(Nm × 10-2)
Femoral Neck 50.8 ± 5.17 53.9 ± 5.74 49.2 ± 3.65
Femoral Shaft 48.1 ± 3.33 47.9 ± 3.99 43.0 ± 4.18**/#
Stiffness
(Nm/° × 10-3)
Femoral Neck 0.78 ± 0.10 0.78 ± 0.12 0.73 ± 0.10
Femoral Shaft 1.05 ± 0.18 1.04 ± 0.09 1.04 ± 0.15
Deflection
(°)
Femoral Neck 23.1 ± 3.00 24.3 ± 2.67 24.0 ± 3.37
Femoral Shaft 16.6 ± 2.53 16.7 ± 1.37 14.4 ± 1.43*/##
Energy absorption
(J × 10-2)
Femoral Neck 1.19 ± 0.12 1.26 ± 0.14 1.15 ± 0.09
Femoral Shaft 1.12 ± 0.08 1.13 ± 0.09 1.01 ± 0.10*/#
Data is presented as mean ± SD. **P < 0.01 significantly different compared to control, #P < 0.05, ##P < 0.01 significantly different compared to 
fenofibrate group.BMC Endocrine Disorders 2009, 9:10 http://www.biomedcentral.com/1472-6823/9/10
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Plasma (A) and femur (B) levels of leptin (ng/ml), plasma (C) and femur (D) levels of adiponectin (ng/ml), plasma levels of oste- ocalcin (ng/ml) (E), and plasma levels of osteoprotegerin (OPG) (pg/ml) (F) in control (CTR) rats (n = 12), fenofibrate (FENO)  (n = 11) and pioglitazone (PIO)-fed (n = 8) rats after 4 months of daily treatment Figure 1
Plasma (A) and femur (B) levels of leptin (ng/ml), plasma (C) and femur (D) levels of adiponectin (ng/ml), 
plasma levels of osteocalcin (ng/ml) (E), and plasma levels of osteoprotegerin (OPG) (pg/ml) (F) in control 
(CTR) rats (n = 12), fenofibrate (FENO) (n = 11) and pioglitazone (PIO)-fed (n = 8) rats after 4 months of daily 
treatment. Data is presented as mean ± SD. *P < 0.05, **P < 0.01, ***P < 0.0001 significantly different compared to control, 
#P < 0.05, ### P < 0.0001 significantly different compared to the fenofibrate group.BMC Endocrine Disorders 2009, 9:10 http://www.biomedcentral.com/1472-6823/9/10
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induced significant changes in RANKL secretion from
MC3T3-E1 cells compared to untreated cells (data not
shown).
Osteoclast differentiation and activity
We found no effect of fenofibrate or pioglitazone on
either differentiation or activity of primary human osteo-
clasts.
Discussion
TZD use has been shown to increase bone loss and frac-
ture risk in women with diabetes mellitus type 2 [17],
decrease BMD in diabetic men [33], and also to decrease
bone formation and BMD in healthy postmenopausal
women [19]. In the present study we have studied the
skeletal effects of pioglitazone which is a selective PPARγ
agonist [8] and fenofibrate which belongs to the class of
fibrates and is mainly a PPARα agonist [34]. Both sub-
stances are well described and are used in the clinic for
treatment of type 2 diabetes mellitus and hypertriglyceri-
demia, respectively [8,9]. We report effects differentiating
the PPARα agonist fenofibrate from the PPARγ agonist
pioglitazone in intact female rats. Our data represent to
our knowledge the first evidence of positive skeletal effects
of fenofibrate. Femoral BMD measured by DXA was sig-
nificantly increased in female rats receiving fenofibrate.
We have previously shown that Wyeth 14643, which is a
model substance for PPARα agonists, leads to a similar
increment in BMD [35], supporting that this effect is
mediated through PPARα activation. The increase in BMD
following administration of fenofibrate was associated
with a decrease in medullary area. Changes in marrow
cavity area could be the result of combined effects on
bone resorption and formation at the endosteal surface.
Our results do, however, not permit differentiation
between these effects. These changes were not reflected in
Table 5: Relative mRNA expression of selected genes in MC3T3-E1 cells
DAY Alcalic phosphatase 
(ALP)
Bone Sialoprotein CD44 Collagen 1 Lipoprotein lipase (LPL)
0 1.00 ± 0.05 1.00 ± 0.44 1.00 ± 0.30 1.00 ± 0.10 No detectable 
expression
4 Control 1.00 ± 0.15 1.00 ± 0.18 1.00 ± 0.03 1.00 ± 0.24 1.00 ± 0.51
Fenofibrate 0.1 μM 0.62 ± 0.11 0.88 ± 0.23 1.05 ± 0.17 0.92 ± 0.18 1.12 ± 0.23
Pioglitazone 0.1 μM 1.06 ± 0.19 1.40 ± 0.62 1.52 ± 0.06 1.17 ± 0.19 0.90 ± 0.01
8 Control 1.00 ± 0.27 1.00 ± 0.54 1.00 ± 0.17 1.00 ± 0.03 1.00 ± 0.12
Fenofibrate 0.1 μM 1.47 ± 0.04 2.19 ± 0.24 1.09 ± 0.06 0.76 ± 0.0 0.81 ± 0.01
Pioglitazone 0.1 μM 1.40 ± 0.16 2.07 ± 1.45 0.81 ± 0.04 0.34 ± 0.04 1.00 ± 0.06
12 Control 1.00 ± 0.12 1.00 ± 0.50 1.00 ± 0.03 1.00 ± 0.05 1.00 ± 0.58
Fenofibrate 0.1 μM 3.91 ± 0.20** 7.40 ± 0.82* 5.04 ± 0.03*** 6.52 ± 0.78** 0.97 ± 0.14
Pioglitazone 0.1 μM 2.40 ± 0.75 3.94 ± 1.29 2.42 ± 0.11** 2.38 ± 1.00 1.93 ± 1.36
DAY Osteocalcin Osteopontin PPARα PPARγ
0 1.00 ± 0.23 1.00 ± 0.14 1.00 ± 0.51 1.00 ± 0.04
4 Control 1.00 ± 0.34 1.00 ± 0.02 1.00 ± 0.05 1.00 ± 0.30
Fenofibrate 0.1 μM 0.54 ± 0.19 0.99 ± 0.14 2.51 ± 0.43* 0.86 ± 0.24
Pioglitazone 0.1 μM 1.38 ± 0.05 0.76 ± 0.02 1.76 ± 0.02* 1.06 ± 0.09
8 Control 1.00 ± 0.20 1.00 ± 0.30 1.00 ± 0.21 1.00 ± 0.06
Fenofibrate 0.1 μM 0.54 ± 0.11 0.73 ± 0.04 2.83 ± 0.40* 0.93 ± 0.05
Pioglitazone 0.1 μM 0.67 ± 0.02 0.34 ± 0.02 0.98 ± 0.08 2.23 ± 0.36*
12 Control 1.00 ± 0.10 1.00 ± 0.71 1.00 ± 0.04 1.00 ± 0.31
Fenofibrate 0.1 μM 2.34 ± 0.01** 2.38 ± 0.39 1.43 ± 0.23 1.20 ± 0.06
Pioglitazone 0.1 μM 1.89 ± 0.27 1.82 ± 2.32 No detectable 
expression
1.98 ± 0.61
PPAR = peroxisome proliferator activated receptor
Data is in presented as mean ± SD, calculated from standard curves and related to housekeeping gene and normalized to controls. Data is from 
three biological replicates, *P < 0.05, **P < 0.01, ***P < 0.001 when compared to controls at same time (two-tailed student t-test).BMC Endocrine Disorders 2009, 9:10 http://www.biomedcentral.com/1472-6823/9/10
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other significant histomorphometric differences, nor
improved mechanical properties of bone.
Rats treated with pioglitazone exhibited the opposite skel-
etal response. They had a significantly lower whole body
BMD and BMC, and tended to have a lower femoral BMD.
These data were further corroborated by histomorphome-
try showing decreased trabecular bone volume and
increased medullary area in femur, suggesting increased
endosteal resorption. Moreover, these changes were
reflected in a decline in ultimate bending moment and
energy absorption in the femoral shaft indicating
increased skeletal fragility. The findings of this study sup-
port previous reports demonstrating a negative impact on
the skeleton of rodents treated with the PPARγ agonist ros-
iglitazone [14-16]. Taken together, these data indicate
positive skeletal effects of PPARα agonists, while PPARγ
activation has a net negative effect on the skeleton. How-
ever, PPAR-independent effects can not be ruled out.
In addition to the effects on BMD, we observed changes in
fat mass and lean mass. In accordance with previous stud-
ies [22,23], an increase in fat mass was found in animals
given pioglitazone. No difference in body weight was
found between the groups.
Leptin has emerged as a significant factor in the regulation
of bone mass, as reviewed by Reid et al. [36]. We observed
a decrease in plasma leptin levels in both fenofibrate and
pioglitazone rats, which is in accordance with previous
studies. Adipose tissue is the strongest determinant of
serum leptin levels. In a study by Damci et al., fenofibrate
treatment of type 2 diabetics with hypertriglyceridemia
was associated with lower serum leptin levels in spite of
unchanged body mass index during the study [37]. Sev-
eral studies describe a suppression of serum leptin in con-
nection with TZDs use in spite of the increased fat mass
[22,23,38]. In our study leptin levels in the protein frac-
tion of crushed femurs were unchanged in fenofibrate rats
compared to controls, while significantly reduced in ani-
mals receiving pioglitazone.
In accordance with previous studies on TZDs, adiponectin
levels were elevated in the pioglitazone group [24,25],
while a significant decrease was observed in the fenofi-
brate rats. This is in contrast to studies in humans where
administration of fibrates is associated with a rise in
plasma adiponectin [26]. Adiponectin-adenovirus treat-
ment increased trabecular bone mass in mice [39],
whereas Reid et al. report increased bone mass in adi-
ponectin knock-out mice [40]. Increasing levels of adi-
ponectin are found to be associated with a decrease in
BMD in postmenopausal women [41]. Data on the effects
of the adipokines leptin and adiponectin on bone are con-
flicting, and it is difficult to interpret the significance of
the observed changes in our study.
The changes in fat mass were associated with reciprocal
effects on lean mass, with the pioglitazone group showing
significantly lower lean mass, and the fenofibrate rats sig-
nificantly higher lean mass. The increase in liver weight in
the fenofibrate group is a well known effect of PPARα acti-
vation [42], and contributes to the elevated lean mass in
this group. After correction for this, lean mass is, however,
still higher in the fenofibrate group than in the two others.
Muscle plays a critical role in bone growth and remode-
ling because the greatest loads on bone arise from muscle
contractions. Therefore, the differences in BMD between
the groups could partly be explained by various effects on
lean mass. This is supported by a positive correlation
between lean mass and BMD, as well as cortical area.
Enhanced osteoclastogenesis leading to bone loss is the
main etiological factor in osteoporosis development.
Osteoclast differentiation is regulated by the coordinated
synthesis and actions of the cytokines RANKL and OPG
produced by bone marrow stromal cells and osteoblasts
[43,44]. In the present study fenofibrate, but not pioglita-
zone, stimulated OPG release from MC3T3-E1 cells while
RANKL release was unaffected by both agents. Since OPG
is an important inhibitor of osteoclast differentiation via
binding of RANKL, these findings indicate an antiresorp-
tive effect of fenofibrate. Our findings are supported by a
newly published study showing that fenofibrate increases
plasma OPG in humans [45]. The observed decrease in
cross-sectional medullary area may be explained by this
effect. It has previously been shown that fenofibrate also
inhibits osteoclast differentiation directly [11]. We were,
Effect of the PPARα agonist fenofibrate and the PPARγ ago- nist pioglitazone on proliferation in MC3T3-E1 preosteoblast  cells Figure 2
Effect of the PPARα agonist fenofibrate and the 
PPARγ agonist pioglitazone on proliferation in 
MC3T3-E1 preosteoblast cells. Data is presented in 
mean ± SD in % of control (unstimulated cells) from four 
parallels in each experiment, and the figure represents data 
from four different experiments. *P < 0.05 significantly differ-
ent compared to control.BMC Endocrine Disorders 2009, 9:10 http://www.biomedcentral.com/1472-6823/9/10
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however, not able to confirm those findings in human
preosteoclasts.
Plasma OPG levels were significantly lower in rats treated
with pioglitazone. Pioglitazone did, however, not affect
the release of OPG or RANKL from MC3T3-E1 cells, and
no effect on osteoclast differentiation or activity was
observed. Enhanced marrow adipogenesis and bone
resorption have also been described in estrogen-deprived
rats treated with rosiglitazone [16]. The increased medul-
lary area observed in our study also suggests an increased
endosteal resorption.
Previous studies have concluded that rosiglitazone affects
the skeleton primarily via a negative impact on bone for-
mation. Rosiglitazone activates adipocyte differentiation
and inhibits osteoblast differentiation [28], and an
increase in fat content and number of adipocytes has been
shown in trabecular bone after administration of rosigli-
tazone [14]. These effects seem to be mediated via activa-
tion of PPARγ2. Rzonca et al. found that expression of the
osteoblast specific marker genes runx2 and alpha1(I) col-
lagen in the tibia was decreased in mice receiving rosigli-
tazone [14], and Kha et al., have demonstrated that the
PPARγ agonist troglitazone induces adipogenesis in
expense of osteogenesis in mesenchymal stem cells [46].
Based on these data one would expect pioglitazone to
interfere with osteoblast formation in a similar manner.
In the present study, however, we were unable to show
any effects of pioglitazone on osteoblast differentiation in
the mouse preosteoblast cell line MC3T3-E1. This might
be explained by the fact that these cells are already com-
mitted to the osteoblastic pathway
In vivo studies have demonstrated that heterozygous
PPARγ-deficient mice have enhanced bone mass as a
result of increased osteoblastogenesis [47], and that the
PPARγhyp/hyp mouse model, which does not express PPARγ
(1 nor 2), has increased bone mass due to favoured oste-
ogenic, rather than adipogenic, differentiation of mesen-
chymal precursor cells [48] Our in vivo data suggest an
effect of the PPARγ agonist mainly on bone resorption.
We have, however, only structural histomorphometric
data, and are not able to differentiate between increased
bone resorption and decreased bone formation.
In contrast, we found that fenofibrate stimulated osteob-
last differentiation, as well as proliferation. The pro-
nounced stimulation of type I collagen mRNA, denotes
increased bone matrix formation. This effect needs to be
confirmed by protein measurements. Our data corre-
spond with previous reports, demonstrating that the
PPARα agonist Wyeth 14643 induces osteoblast matura-
tion of preosteoblasts, indicating a positive effect of
PPARα agonists on bone formation [4]. This notion is fur-
ther supported by the increased levels of plasma osteocal-
cin in fenofibrate rats in our study. Theoretically, the
decrease in marrow cavity area could be a result of com-
bined effects on bone resorption and formation at the
endosteal surface.
Conclusion
We show opposite skeletal effects of PPARα and γ agonists
in intact female rats. We report for the first time that fenof-
ibrate increases femoral BMD and decreases medullary
area in femur. This appears to be associated with changes
in cortical bone, since trabecular bone was unchanged.
The stimulatory effect of fenofibrate on osteoblast prolif-
eration and differentiation, as well as OPG release, consti-
tutes also new findings. The observed negative skeletal
effects of pioglitazone confirm previous findings with ros-
iglitazone in rodents. These findings are of particular
interest in light of recent human studies showing
enhanced bone loss and increased fracture risk in TZDs
users [17-19,33,49]. It is conceivable that further studies
Effect of PPARα agonist fenofibrate (A) and PPARγ agonist  pioglitazone (B) on osteoprotegerin (OPG) release from  MC3T3-E1 preosteoblast cells Figure 3
Effect of PPARα agonist fenofibrate (A) and PPARγ 
agonist pioglitazone (B) on osteoprotegerin (OPG) 
release from MC3T3-E1 preosteoblast cells. Amount 
of OPG is related to the amount of total protein in each sam-
ple. Data is presented in mean ± SD in % of control (unstim-
ulated cells) from two parallels, and the figure represents 
data from four different experiments. *P < 0.05, **P < 0.01, 
***P < 0.001 significantly different compared to control.BMC Endocrine Disorders 2009, 9:10 http://www.biomedcentral.com/1472-6823/9/10
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on the effects of PPAR agonists may give new insights in
the regulation of bone mass and pathogenesis of oste-
oporosis, insights, which may potentially offer new treat-
ment options.
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